Promising results from this trial, including the favorable toxicity profile of TAK‐659 and the lack of significant interaction or overlapping side effects with R‐CHOP, justify the use of TAK‐659 in the front‐line setting in DLBCL, in combination with the standard of care regimen of R‐CHOP. The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.